What Happened
- The Drugs Controller General of India (DCGI), in collaboration with State Drug Controllers, has launched targeted enforcement actions across the pharmaceutical supply chain to curb malpractices in the sale and use of GLP-1 receptor agonist weight-loss drugs.
- A series of inspections and audits were conducted at 49 entities including online pharmacy warehouses, drug wholesalers, brick-and-mortar retailers, wellness clinics, and slimming centres.
- The DCGI has issued an advisory explicitly prohibiting surrogate advertisements — a practice where companies promote "awareness" of the drug's category to indirectly drive consumer demand without appearing to advertise a prescription drug.
- State regulators have been directed to take immediate action against non-compliant entities; penalties include cancellation of drug licences, financial penalties, and prosecution under the Drugs and Cosmetics Act, 1940.
- The crackdown is part of a broader concern about the explosive growth of the GLP-1 market in India following generic entry, with the injectable segment recording 177% year-on-year sales growth.
Static Topic Bridges
CDSCO and India's Drug Regulatory Architecture
India's drug regulatory system is structured as a concurrent jurisdiction model: the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare handles central-level approvals, while State Licensing Authorities (SLAs) issue manufacturing and retail licences at the state level. The Drugs Controller General of India (DCGI) heads CDSCO and is the central licensing authority for new drugs, clinical trials, and imported drugs. This dual structure has historically created gaps, as states have sometimes issued manufacturing licences without prior CDSCO clearance.
- CDSCO functions: New drug approval, clinical trial regulation, import licensing, post-market surveillance, quality standards
- DCGI powers: Under the Drugs and Cosmetics Act, 1940 — can prohibit manufacture and sale under Section 26A; can issue advisories; can direct state regulators
- State Drug Controllers: Responsible for licensing of manufacturers and pharmacies within the state; enforce Act provisions at the retail level
- The "dual regulator" problem: Central government approves new drugs; states license manufacturers — leading to cases where FDCs and other drugs enter the market through states without CDSCO approval
- Schedule H and H1 classification: GLP-1 drugs fall under Schedule H (prescription-only); pharmacies are legally required to dispense only against a valid prescription
Connection to this news: The DCGI's collaboration with State Drug Controllers represents a coordinated federal enforcement action to close the compliance gap in the GLP-1 supply chain — recognising that central advisory alone is insufficient without state-level enforcement.
Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 prohibits advertisements of drugs that claim to cure diseases specified in the schedule to the Act, and more broadly prohibits direct-to-consumer advertising of prescription drugs. Advertising prescription-only medicines (Schedule H/H1) to the general public is illegal under the Rules framed under the Drugs and Cosmetics Act, 1940.
- Enacted 1954; administered by the Ministry of Health and Family Welfare
- Prohibits advertisements claiming to cure: diseases of the sexual organs, HIV/AIDS, cancer, mental illnesses, and other scheduled conditions
- Prescription drug advertising: Permitted only in professional medical journals directed at healthcare professionals; not in general media
- Surrogate advertising: A practice where a company promotes a brand name/logo through an ostensibly different product or "awareness" campaign to build brand recognition without technically advertising the prohibited product — now explicitly banned by the DCGI advisory
- The Consumer Protection Act, 2019 also creates liability for misleading advertisements under the Central Consumer Protection Authority (CCPA)
Connection to this news: The DCGI's advisory against surrogate advertisements specifically targets companies that were using "disease awareness" campaigns — promoted as educational content — to indirectly build demand for GLP-1 weight-loss drugs among consumers.
Post-Market Surveillance and Pharmacovigilance in India
India operates a national Pharmacovigilance Programme of India (PvPI), launched in 2010 and coordinated by the Indian Pharmacopoeia Commission (IPC) in Ghaziabad under the Ministry of Health and Family Welfare. PvPI collects adverse drug reaction (ADR) reports from healthcare professionals and patients, analyses safety signals, and recommends regulatory action to CDSCO. This forms the basis for post-market safety decisions on drugs already approved.
- PvPI: National pharmacovigilance programme; coordinates with WHO's global pharmacovigilance network (Uppsala Monitoring Centre)
- ADR reporting: Voluntary (healthcare professionals, patients) and mandatory (pharmaceutical manufacturers for serious ADRs)
- GLP-1 safety concerns under surveillance: Pancreatitis, thyroid tumour risk, cardiovascular effects, gastrointestinal complications, suicidal ideation (flagged by European regulators for some GLP-1 agents)
- CDSCO's Drug Safety Advisory Committees: Expert bodies that review ADR data and recommend label changes, additional warnings, or bans
- India's challenge: Off-label use and sale without prescription means ADRs from non-clinical contexts are underreported
Connection to this news: The intensified regulatory surveillance is partly a proactive pharmacovigilance measure — ensuring that the explosive growth in GLP-1 use is accompanied by appropriate medical oversight to capture and act on adverse drug reaction signals before a safety crisis develops.
Key Facts & Data
- Entities inspected/audited: 49 (online pharmacies, wholesalers, retailers, wellness/slimming clinics)
- GLP-1 injectable market growth: 177% YoY to ₹1,446 crore (Feb 2026 vs Feb 2025)
- Generic versions entered market: 15+ Indian manufacturers after patent expiry; price drop 50–70%
- DCGI surrogate advertising advisory: March 10, 2026
- Regulatory penalties: Licence cancellation, financial penalties, prosecution under Drugs and Cosmetics Act, 1940
- Section 26A, Drugs and Cosmetics Act, 1940: Central government power to ban drugs in public interest
- GLP-1 drugs classification in India: Schedule H (prescription-only)
- PvPI launch year: 2010; coordinating body: Indian Pharmacopoeia Commission (IPC), Ghaziabad
- Drugs and Magic Remedies (Objectionable Advertisements) Act: 1954